Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Phase 1 Completed
32 enrolled 15 charts
AML
Phase 1 Completed
10 enrolled
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase 1 Terminated
23 enrolled
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Terminated
9 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
39 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
13 enrolled
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
25 enrolled
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
46 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1 Completed
90 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
35 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
Phase 1 Completed
58 enrolled
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Terminated
24 enrolled
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Phase 1 Completed
73 enrolled
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Phase 1 Completed
37 enrolled
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Terminated
88 enrolled
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
Phase 1 Completed
36 enrolled
Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
58 enrolled
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Phase 1 Terminated
50 enrolled
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
24 enrolled
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
Phase 1 Completed